Activity of imipenem-relebactam against a large collection of pseudomonas aeruginosa clinical isolates and isogenic β-lactam-resistant mutants

Simple item page
UDC.coleccionInvestigación
UDC.departamentoFisioterapia, Medicina e Ciencias Biomédicas
UDC.grupoInvInvestigación en Microbiología (INIBIC)
UDC.institutoCentroINIBIC - Instituto de Investigacións Biomédicas de A Coruña
UDC.issue2
UDC.journalTitleAntimicrobial Agents and Chemotherapy
UDC.volume64
dc.contributor.authorFraile-Ribot, Pablo Arturo
dc.contributor.authorZamorano, Laura
dc.contributor.authorOrellana, Rocío
dc.contributor.authordel Barrio-Tofiño, Ester
dc.contributor.authorSánchez-Diener, Irina
dc.contributor.authorCortés-Lara, Sara
dc.contributor.authorLópez-Causapé, Carla
dc.contributor.authorCabot, Gabriel
dc.contributor.authorBou, Germán
dc.contributor.authorMartínez-Martínez, Luis
dc.contributor.authorOliver, Antonio
dc.date.accessioned2025-11-06T10:38:59Z
dc.date.available2025-11-06T10:38:59Z
dc.date.issued2020-01-27
dc.description.abstract[Abstract] Imipenem and imipenem-relebactam MICs were determined for 1,445 Pseudomonas aeruginosa clinical isolates and a large panel of isogenic mutants showing the most relevant mutation-driven β-lactam resistance mechanisms. Imipenem-relebactam showed the highest susceptibility rate (97.3%), followed by colistin and ceftolozane-tazobactam (both 94.6%). Imipenem-relebactam MICs remained ≤2 μg/ml in all 16 isogenic PAO1 mutants and in 8 pairs of extensively drug-resistant clinical strains that had developed resistance to ceftolozane-tazobactam and ceftazidime-avibactam due to mutations in OXA-10 or AmpC.
dc.description.sponsorshipThe work was supported by MSD and by Plan Nacional de I+D+i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016), and grant PI18/00076 cofinanced by European Regional Development Fund (ERDF) “A way to achieve Europe,” Operative Program Intelligent Growth 2014–2020. The work was partially financed by MSD through Investigator Initiated Studies Program to A.O.
dc.identifier.citationFraile-Ribot PA, Zamorano L, Orellana R, Del Barrio-Tofiño E, Sánchez-Diener I, Cortes-Lara S, López-Causapé C, Cabot G, Bou G, Martínez-Martínez L, Oliver A; GEMARA-SEIMC/REIPI Pseudomonas Study Group. Activity of imipenem-relebactam against a large collection of pseudomonas aeruginosa clinical isolates and isogenic β-lactam-resistant mutants. Antimicrob Agents Chemother. 2020 Jan 27;64(2):e02165-19.
dc.identifier.doi10.1128/aac.02165-19
dc.identifier.issn0066-4804
dc.identifier.urihttps://hdl.handle.net/2183/46306
dc.language.isoeng
dc.publisherAmerican Society of Microbiology
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII)/PI18%2F00076/ES/ANALISIS DEL RESISTOMA IN VITRO E IN VIVO: DESARROLLO DE NUEVAS HERRAMIENTAS PARA OPTIMIZAR EL DIAGNOSTICO Y TRATAMIENTO DE LAS INFECCIONES POR PSEUDOMONAS AERUGINOSA/
dc.relation.urihttps://doi.org/10.1128/aac.02165-19
dc.rightsAttribution 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectPseudomonas aeruginosa
dc.subjectAntibiotic resistance
dc.subjectImipenem-relebactam
dc.subjectMultidrug resistance
dc.subjectWhole-genome sequencing
dc.subjectβ-lactam resistance mechanisms
dc.titleActivity of imipenem-relebactam against a large collection of pseudomonas aeruginosa clinical isolates and isogenic β-lactam-resistant mutants
dc.typejournal article
dc.type.hasVersionAM
dspace.entity.typePublication
relation.isAuthorOfPublication909e08d1-6ed1-4b99-9e9e-c64eb72e7dea
relation.isAuthorOfPublication.latestForDiscovery909e08d1-6ed1-4b99-9e9e-c64eb72e7dea

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
zamorano_activity_2020.pdf
Size:
450.98 KB
Format:
Adobe Portable Document Format
Download

Collections

Investigación (FFISIO)